US FDA orders post-market studies for needleless connectors
This article was originally published in SRA
The US Food and Drug Administration has written to nine companies manufacturing positive displacement needleless connectors asking them to conduct post-market studies to assess whether their products are associated with a higher rate of device-associated bloodstream infections when compared with other types of needleless connectors.
You may also be interested in...
The International Pharmaceutical Regulators Programme has documented various approaches currently being used for the clinical comparability of biosimilar monoclonal antibodies in different jurisdictions.
Remote inspections are here to stay, and global regulators are aligning efforts to develop consensus on how these should be conducted.
Device companies operating in Canada are being advised to review their internal procedures in anticipation of new postmarket requirements that come into force this year.